Use of recombinant factor VIII Advate in paediatric patients First steps in the Czech Republic

Abstract

Until gene therapy is available, the subtitution therapy remains the basic therapeutic strategy in hemophilia. Currently, the efficacy and safety are the critical attributes of substitution products.

Now most haemophilic children and virtually all adults are treated with highly purified plasma-derived FVIII a FIX concentrates but modern trend is using of recombinant factors VIII and IX in the developing world. The main reason is their better microbiological safety.

The article describes the first experiences with 18 czech pediatric patients treated with this preparations.

Keywords

• Haemophilia A
• substitution therapy
• plasma derived FVIII
• recombinant FVIII
• safety of therapy
• microbiological safety
• czech pediatric haemophiliac
• first experiences